Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Bristol Myers Squibb Gets FDA Approval for Myeloma Treatment

13 August 2026 · By · Wire by Fusion42

Published

13 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at marketwatch.com →

◆ Verified

Fusion42 · 13 August 2026 · Fusion42 review

Bristol Myers Squibb received FDA approval for Zenbexus (iberdomide) in combination with daratumumab, hyaluronidase-fihj, and dexamethasone to treat multiple myeloma in adults who have had at least one prior therapy line.

This Wire brief sits within Fusion42's coverage of Biotech, and 12 sources have reported it between 13 Aug 2026 and 17 Aug 2026.

◆ ◆ The Wire takeaway

New FDA approval opens a treated multiple myeloma market segment for you with Zenbexus combination therapy, but full commercialisation depends on upcoming trial data.

◆ Coverage

12 sources · first reported 13 Aug 2026 · latest 17 Aug 2026

◆ Topics

Biotechfda-approvalmultiple-myelomadrug-combinationbiopharmaclinical-trial